[go: up one dir, main page]

WO1993018745A1 - Utilisation d'un revetement antiviral avec des articles en latex tels que les preservatifs - Google Patents

Utilisation d'un revetement antiviral avec des articles en latex tels que les preservatifs Download PDF

Info

Publication number
WO1993018745A1
WO1993018745A1 PCT/CA1993/000115 CA9300115W WO9318745A1 WO 1993018745 A1 WO1993018745 A1 WO 1993018745A1 CA 9300115 W CA9300115 W CA 9300115W WO 9318745 A1 WO9318745 A1 WO 9318745A1
Authority
WO
WIPO (PCT)
Prior art keywords
latex
amount
barrier item
weight
latex barrier
Prior art date
Application number
PCT/CA1993/000115
Other languages
English (en)
Inventor
George Martyn Livingston
Original Assignee
Geda International S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geda International S.A. filed Critical Geda International S.A.
Publication of WO1993018745A1 publication Critical patent/WO1993018745A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
    • A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B42/00—Surgical gloves; Finger-stalls specially adapted for surgery; Devices for handling or treatment thereof

Definitions

  • This invention relates to anti-viral composi ⁇ tions , and more particularly to anti-viral compositions for external topical application to mammalian skin.
  • Viral transmission from body to body as a result of body surface contact and body fluid intermingling is one of the principal ways in which viruses such as hepatitis, herpes, HIV and the like are spread.
  • health workers such as ambulance personnel, nurses, doctors, operations theatre attendants and the like, who must administer to and consequently frequently engage in body contact with virally infected persons.
  • the most commonly recommended form of protection against such viral infections has been the protective skin barrier method namely the use of latex gloves by health care workers and the use of latex condoms by those exposed to sexually transmitted viruses.
  • the present invention provides an anti-viral gel formulation for use in conjunction with viral barrier items such as latex gloves and condoms.
  • the formulation contains a very small, skin acceptable amount of a strong disinfec ⁇ tant or antiseptic substance, formulated into a semi-solid, gel consistency with aqueous based, skin acceptable carrier materials, for application to mammalian skin under viral barrier items such as latex• gloves and condoms.
  • the disinfectant or antiseptic substance kills the harmful virus on contact, even in the necessarily small concentra ⁇ tions required to render the compositions of the present invention skin acceptable.
  • the user is accordingly pro ⁇ vided with a double protection against viral infection from an infected body which must be contacted, namely the viral barrier item and the antiseptic or disinfectant gel beneath it.
  • a latex barrier item adapted to be fitted over a body part to inhibit viral transmission thereto, said latex barrier item having an outer surface and an inner surface to contact the body part, said inner surface having a layer of semi-solid, anti-viral gel or cream comprising an alkyl benzyl quaternary ammonium halide disinfectant in an amount of from about 0.005-0.1% by weight, a non-ionic or cationic surfactant in an amount of from about 0.01-0.1% by weight, and a lubricious non-toxic hypoallergenic water compatible thickener in an amount chosen to give semi-solid, creamy consistency to the composition, and water.
  • an alkyl benzyl quaternary ammonium halide disinfectant in an amount of from about 0.005-0.1% by weight
  • a non-ionic or cationic surfactant in an amount of from about 0.01-0.1% by weight
  • a lubricious non-toxic hypoallergenic water compatible thickener in an amount chosen to give semi-solid, creamy
  • the alkyl benzyl quaternary ammonium halide disinfectants used in the present invention are known compounds, many of which have previously been sold and used for disinfecting purposes in non-skin contacting applica ⁇ tions. Thus, they are sold for purposes of making up disinfectant wash solutions for floors, walls, operating surfaces and the like, but always with strong warnings to avoid skin contact with them if at all possible. They are powerful poisons and skin irritants, as well as powerful disinfectants. According to the present invention, they will destroy harmful viruses such as hepatitis, herpes simplex types 1 and 2 and HIV when they are present in formulations in such low concentrations that they are skin acceptable. These viruses in fact are not difficult to kill when encountered in isolation in external body fluids or secretions.
  • the strong disinfectant is preferably used in the composi ⁇ tion of the present invention in amounts from 0.005-0.5% by weight, most preferably from 0.005-0.001% by weight.
  • Specific examples of such strong disinfectants for use in the present invention include alkyl dimethyl benzyl ammon ⁇ ium chloride and alkyl dimethylethylbenzyl ammonium chlor ⁇ ide, in which the alkyl portions are C 12 -C 18 in length, and mixtures thereof, and myristylbenzalkonium chloride.
  • Such a suitable mixture is available commercially under the trade name MAQUAT MQ2525M - 50%, from Mason Chemical Company, Chicago, Illinois, and under the trade name BTC 2125M from Stepan Company, North Field, Illinois.
  • compositions according to the present invention also include a small amount of a non-ionic or cationic surfactant to act as a wetting agent for the disinfectant. This improves the spreading of the disinfectant over the skin area to which it is applied.
  • the surfactant is suitably present in amounts similar to those of the disin ⁇ fectant, i.e. 0.01-0.1% by weight, preferably 0.01-0.05% by weight.
  • Examples of specific useful surfactants of these classes include the polyoxyethylene - based types such as those of the octoxynol series , which are polyethylene glycol p-isooctylphenyl ethers such as octoxynol-9 (Triton X - 100), those of the nonoxynol series, which are polyoxy ⁇ ethylene nonylphenyl ethers, of various numbers of ethylene oxide units, e.g. nonoxydol 9 and nonoxydol 10. These have the advantage for use in the present invention in that they also have spermatocidal properties.
  • polyoxyethylene - based types such as those of the octoxynol series , which are polyethylene glycol p-isooctylphenyl ethers such as octoxynol-9 (Triton X - 100)
  • those of the nonoxynol series which are polyoxy ⁇ ethylene nonylphenyl ethers, of
  • Non-Ionic surfactants are the polyoxyethyl alcohols such as those sold under the trade name "Siponic.”
  • Other choices of surfactant may be made by consulting the standard reference work: “Non-Ionic Surfactants,” edited by M.J.Schick, Dekker, New York, 1967.
  • the overriding criteria of choice are compatibility with skin and with the chosen strong disinfectant, at the chosen amounts.
  • the other ingredients of the composition of the present invention are a non-toxic hypoallergenic water compatible thickener, and water, in proportions suitable to provide a product of a gel, semi-solid consistency resembl ⁇ ing that of hand cream.
  • a wide range of such thickeners is available on the market, and commonly used in the cosmetic and pharmaceutical formulations industries. They are well known to those skilled in the art.
  • Various cellulose derivatives can be used for this purpose, for example methyl cellulose and the various sodium carboxymethyl cellulose compounds such as Carbomers 910, 934, 934P, 940, 941 and 1342; and Carbopols 940, 941 and 930 (from Goodyear) .
  • Preferred are those which also confer a degree of lubricity on the final composition.
  • aquasonic gel a gel composition commonly used for body contact with ultra sound diagnostic test appar ⁇ atus. It suitably comprises from 1 - 80%, preferably from 20 - 80% and most preferably from 30-40% by weight of the composition. The amount is chosen on the basis of the desired consistency of the final product, and on the basis of the precise choice of thickener - some have greater thickening power than others.
  • composition of the present invention can contain one or more emollients such as glycerine, lanolin, aloe vera, paraffin oils, glycerol monostearate, myrj compounds, Tween, PEG compounds, sodium lauryl sulphate, etc., and mixtures of two or more of them, to improve the lubricity and general oiliness of the composition. It can also if desired contain various perfumes and colorants. Any ingredients which are used must be skin compatible, inert towards the active ingredient, and of a nature and used in an amount which does not destabilize or upset the general creamy consistency of the formulation.
  • the formulations according to the present inven ⁇ tion can be prepared using standard cosmetic or pharma ⁇ ceutical gel formulating procedures and equipment. There is no particular, critical order of addition of components, mixing temperatures or the like, provided that a homogene ⁇ ous, reasonably stable end product is achieved.
  • the specific, most preferred formulation accord ⁇ ing to the present invention has the following composition (parts by weight) : Water 53 .74
  • Methyl Cellulose (4000 cps) 1.0
  • the preparation was made by simple mixing of ingredients in a container, at room temperature. It was then tested for its anti-viral effectiveness in vitro against Herpes Hominis types 1 and 2.
  • Virus suspensions were clarified by low speed centrifugation and kept frozen at -70°C. Infectivity was titrated and expressed in TCID 50/0.1 ml. Equal volumes of virus were added to the test formulation in the concentration given in the following table of results. Thus, the most concentrated emulsion was 10% after the virus was added.
  • test formulation activity After incubation the residual test formulation activity had been reduced to an undetectable level in all the test formulations/virus mixtures at concentrations of 10, 5, 2.5, l, 0.5, 0.05% of test formulation.
  • the con ⁇ trols consisting of medium contained 3.0 and 4.0 log ten TCID 50/0.1 ml. The reductions in the titers of virus after contacting with 10, 5, 2.5, 1, 0.5, 0.05% test formulation were in excess of 2 log 10 TCID 50 .
  • test formulation/virus mixtures were incubated at 37°C for.10 minutes and the same inactivity resulted with both types of herpes virus.
  • a cream was formulated having the same ingredi ⁇ ents in the same relative proportions as described above in Example 1.
  • a cream formulation according to the specific, most preferred formulation given above was tested for its effectiveness against human hepatitis B in the morphologi ⁇ cal alteration test and destruction test.
  • a human hepatitis B virus (HBV) formulation was prepared having 5.0% bovine calf serum (40 ⁇ l) with 760 ⁇ l HBV (Gilbralter Biological Laboratories, Inc., HBV Pool 11, GBL reference no. 018-272A-153) .
  • HBV Human hepatitis B virus
  • Into 25 x 150 mm glass tubes was injected 2 ml of the cream formulation and 0.2 ml of the HBV formulation. The mixtures were vortexed vigor ⁇ ously for one minute. The reaction was stopped by adding 18 ml of Trypticase Soy Broth containing 20% serum, vortex- ing well and placing into ice bath.
  • Virus controls were prepared in the same way by pipetting 0.2 ml HBV into 2.0 ml phosphate buffered saline (PBS). The reaction mixtures were concentrated by ultracentrifugation with appropriate sucrose gradients, the supernatant gently poured off, and the pellets were re-suspended with a 0.5 ml PBS, with similar pellets being combined.
  • the HBV particles were purified by late-zonal ultracentrifugation in a 60-5% linear gradient (sucrose), and fractionated. Dane particle fractions having a refractive index between 1.396 and 1.404 were saved and pooled.
  • Negative staining was used to detect morphologi ⁇ cally altered virions. For this, 5% uranyl acetate in water, at pH 3.5, was used, with blotting. Thirty or more fields from six randomly selected squares were observed with a Philips transmission electron microscope, and thoroughly enumerated for each of the four alteration phases AP0, API, AP2 and AP3. No morphologically intact virions were observed, only highly morphologically altered, AP2 and AP3 forms, which are non-infectious. In contrast, the control samples evidenced the great majority of virions to be morphologically intact and in the infectious (AP0 or API) phases.
  • the mechanism of action of the composition of the invention is probably membrane disruption.
  • the human T-cell leukemia virus type 1 immortal ⁇ ized cell line MT-2 was maintained in growth medium (Dulbecco's Modified Eagle's Medium with 15% heat-inacti ⁇ vated fetal calf serum, 2 mm glutamine, 100 iu of penicillin per ml and 100 ⁇ g of streptomycin per ml).
  • growth medium Dulbecco's Modified Eagle's Medium with 15% heat-inacti ⁇ vated fetal calf serum, 2 mm glutamine, 100 iu of penicillin per ml and 100 ⁇ g of streptomycin per ml).
  • HIV-1 (IIIB) the prototype laboratory strain, was obtained from the culture supernatant of H9 infected cells and was concentrated to 1,000 x by banding in sucrose. Filtered viral stocks were aliquoted and stored at -85°C until used. The virus stock was determined by an end point titration method using MT-2 cells in a 96-well microtiter plate configuration. The virus stock contained a TCID 50 virus titer of 5.50 log 10 TCID 50/ml calculated by the Reed-Muench method.
  • MT-2 cells in exprudential growth phase were exposed to various dilutions of compounds. After 4 days, the cell viability was assessed by the Tryptan-Glu exclusion method and compared to controls without drug.
  • Virus stocks were thawed and diluted with phos ⁇ phate buffered saline to obtain the required amounts of virus necessary for inactivation assay experiments. Untreated virus served as the TCID 50 control for this experiment. After a one minute exposure of HIV-1 with the compound, sequential ten-fold dilutions of the treated or untreated virus control were prepared in PBS and each dilution was used to infect MT-2 cells as previously described. Virus expression was monitored by the presence of syncytium formation. HIV-induced syncytium formation was assessed after 6 days of culture using a syncytium- formation assay.
  • the compound according to the invention yielded a reduction in HIV infectivity of greater than 2.5 log 10 TCID 50/ml, when compared with untreated controls after one minute of exposure at room temperature (23 - 27°C).
  • the latex gloves contained a residue of starch lubricant powder, in conventional form. In another case, the glove contained no powder. The gloves were left in place on the users hands for 16 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un lait ou une crême antiviral, devant être appliqué sur la peau d'un mammifère sous un élément de protection de la peau tel qu'un gant chirurgical ou un préservatif, comprend une très petite dose tolérable par la peau d'un désinfectant à base d'halogénure d'ammonium quaternaire de benzyle d'alkyle, une très petite dose tolérable par la peau d'un agent tensioactif non ionique ou cationique, un épaississant tel qu'un gel aquasonique, un émollient tel que la glycérine, et de l'eau.
PCT/CA1993/000115 1992-03-23 1993-03-19 Utilisation d'un revetement antiviral avec des articles en latex tels que les preservatifs WO1993018745A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85619092A 1992-03-23 1992-03-23
US07/856,190 1992-03-23

Publications (1)

Publication Number Publication Date
WO1993018745A1 true WO1993018745A1 (fr) 1993-09-30

Family

ID=25323038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1993/000115 WO1993018745A1 (fr) 1992-03-23 1993-03-19 Utilisation d'un revetement antiviral avec des articles en latex tels que les preservatifs

Country Status (3)

Country Link
AU (1) AU3882093A (fr)
CA (1) CA2108143A1 (fr)
WO (1) WO1993018745A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026134A1 (fr) * 1994-03-28 1995-10-05 The Trustees Of Columbia University In The City Of New York Composition pour l'inactivation d'agents irritants dans des liquides
RU2138613C1 (ru) * 1998-05-18 1999-09-27 Волго-Уральский хозрасчетный центр научно-технических услуг "Нейтрон" Способ доставки геофизических приборов на кабеле в горизонтальные скважины
US5985918A (en) * 1996-12-04 1999-11-16 The Trustees Of Columbia University In The City Of New York Zinc-based antiirritant creams
RU2161043C1 (ru) * 2000-04-13 2000-12-27 Гапонюк Петр Яковлевич Средство интимного назначения для мужчин
GB2370277A (en) * 2000-12-21 2002-06-26 Matang Mfg Sdn Bhd Plant-based emolient-containing glove and method for making same
EP1408941A4 (fr) * 2000-01-10 2006-01-25 Zetetic Res Inc Composition pharmaceutique et procede d'utilisation correspondant
EP1545405A4 (fr) * 2002-05-10 2008-06-18 Coloplast As Catheters externes males
EP1676912A3 (fr) * 1997-09-02 2008-12-31 Insight Biopharmaceuticals Ltd. Equipement médical contenant un polypeptide présentant une activité d'héparanase
US7790376B2 (en) 1997-09-02 2010-09-07 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use in research and medical applications
EP1590009A4 (fr) * 2002-10-22 2010-11-03 Allegiance Corp Composition de revetement pour surface en contact avec la peau d'articles elastomeriques et articles contenant ladite composition
US7879365B2 (en) 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
CN101716354B (zh) * 2009-12-04 2012-07-18 广东工业大学 一种超声耦合剂
US20130079661A1 (en) * 2011-06-29 2013-03-28 Leah Tolosa Luminescence based noninvasive remote parameter sensor and sensing method
USRE45435E1 (en) 2002-02-07 2015-03-24 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
US9421263B2 (en) 2003-07-17 2016-08-23 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623087A1 (fr) * 1987-03-13 1989-05-19 Medic 44 Sarl Dispositif preservatif actif masculin et/ou feminin
EP0427997A2 (fr) * 1989-11-10 1991-05-22 Germo S.P.A. Préservatif
WO1992009256A1 (fr) * 1990-12-03 1992-06-11 Medical Polymers, Inc. Lubrifiant a base d'eau pour les tissus humains
EP0475664B1 (fr) * 1990-09-10 1993-11-10 Dow Corning France S.A. Composition de lubrifiant et son utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623087A1 (fr) * 1987-03-13 1989-05-19 Medic 44 Sarl Dispositif preservatif actif masculin et/ou feminin
EP0427997A2 (fr) * 1989-11-10 1991-05-22 Germo S.P.A. Préservatif
EP0475664B1 (fr) * 1990-09-10 1993-11-10 Dow Corning France S.A. Composition de lubrifiant et son utilisation
WO1992009256A1 (fr) * 1990-12-03 1992-06-11 Medical Polymers, Inc. Lubrifiant a base d'eau pour les tissus humains

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPIL Section Ch, Week 8316, Derwent Publications Ltd., London, GB; Class A96, AN 83-37482K *
GEL LUBRIFIANT PHARMATEX *
L. VIDAL 'DICTIONNAIRE VIDAL' 1991 , EDITIONS DU VIDAL , PARIS, FR *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026134A1 (fr) * 1994-03-28 1995-10-05 The Trustees Of Columbia University In The City Of New York Composition pour l'inactivation d'agents irritants dans des liquides
US5708023A (en) * 1994-03-28 1998-01-13 The Trustees Of Columbia University In The City Of New York Zinc gluconate gel compositions
US6037386A (en) * 1994-03-28 2000-03-14 The Trustees Of Columbia University In The City Of New York Composition for inactivating irritants in fluids
US5985918A (en) * 1996-12-04 1999-11-16 The Trustees Of Columbia University In The City Of New York Zinc-based antiirritant creams
US7790376B2 (en) 1997-09-02 2010-09-07 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use in research and medical applications
EP1676912A3 (fr) * 1997-09-02 2008-12-31 Insight Biopharmaceuticals Ltd. Equipement médical contenant un polypeptide présentant une activité d'héparanase
RU2138613C1 (ru) * 1998-05-18 1999-09-27 Волго-Уральский хозрасчетный центр научно-технических услуг "Нейтрон" Способ доставки геофизических приборов на кабеле в горизонтальные скважины
EP1408941A4 (fr) * 2000-01-10 2006-01-25 Zetetic Res Inc Composition pharmaceutique et procede d'utilisation correspondant
RU2161043C1 (ru) * 2000-04-13 2000-12-27 Гапонюк Петр Яковлевич Средство интимного назначения для мужчин
GB2370277B (en) * 2000-12-21 2005-01-05 Matang Mfg Sdn Bhd Plant-based emollient-containing glove and method for making same
US6589544B2 (en) 2000-12-21 2003-07-08 Matang Manufacturing Sdn. Bhd. Aloe vera impregnated elastomeric article and method of manufacture
GB2370277A (en) * 2000-12-21 2002-06-26 Matang Mfg Sdn Bhd Plant-based emolient-containing glove and method for making same
US7879365B2 (en) 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
USRE45435E1 (en) 2002-02-07 2015-03-24 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
EP1545405A4 (fr) * 2002-05-10 2008-06-18 Coloplast As Catheters externes males
US8835014B2 (en) 2002-10-22 2014-09-16 Allegiance Corporation Coating composition for skin-contacting surface of elastomeric articles and articles containing the same
EP1590009A4 (fr) * 2002-10-22 2010-11-03 Allegiance Corp Composition de revetement pour surface en contact avec la peau d'articles elastomeriques et articles contenant ladite composition
US9421263B2 (en) 2003-07-17 2016-08-23 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof
CN101716354B (zh) * 2009-12-04 2012-07-18 广东工业大学 一种超声耦合剂
US20130079661A1 (en) * 2011-06-29 2013-03-28 Leah Tolosa Luminescence based noninvasive remote parameter sensor and sensing method
US9560974B2 (en) * 2011-06-29 2017-02-07 University Of Maryland Baltimore County Luminescence based noninvasive remote parameter sensor and sensing method

Also Published As

Publication number Publication date
CA2108143A1 (fr) 1993-09-24
AU3882093A (en) 1993-10-21

Similar Documents

Publication Publication Date Title
US5725875A (en) Protective skin composition
WO1993018745A1 (fr) Utilisation d'un revetement antiviral avec des articles en latex tels que les preservatifs
DE69533724T2 (de) Zusammensetzung zum inaktivieren von reizstoffen in flüssigkeiten
EP0395215B1 (fr) Composition protectrice sous forme d'un gel
EP0733361B1 (fr) Procédé servant à inactiver les virus à enveloppe
JP2005514325A (ja) 抗微生物ナノエマルジョンの組成物および方法
EP0640345A2 (fr) Composition inhibitant la transmission du SIDA, contenant des sels d'argent avec un détergent
AU5045390A (en) Biodegradable disinfectant
US20090186056A1 (en) Compositions and methods for preventing infection
DE69324393T2 (de) Mittel auf Basis von Antiseptiken und ihre Verwendungen
DK173716B1 (da) Ikke-farmaceutisk komposition som indeholder en overfladeaktiv forbindelse og en fluorforbindelse
US20020198265A1 (en) Antiseptic spermicidal composition and means for its application
EA000817B1 (ru) Дерматологическая антисептическая композиция и способ ее получения
JPS6333326A (ja) 抗菌剤組成物
CN1092937A (zh) 一种可用于乳胶病毒屏护器具的抗病毒涂料
CA2132688A1 (fr) Composition spermicide antiseptique et methode d'application
CN112891323B (zh) 一种抗hiv外用消毒剂及其制备方法
WO2000072839A1 (fr) Composition spermicide antiseptique et son instrument d'application
CA2781379C (fr) Formulations topiques pour la prevention de maladies transmissibles sexuellement et methodes de production desdites formulations
US8409557B2 (en) Topical formulations for the prevention of sexually transmitted disease and methods of producing the same
JP2010209109A (ja) 抗微生物ナノエマルジョンの組成物および方法
NZ600568B (en) Topical formulations for the prevention of sexually transmitted disease and methods of producing the same
HK1189513B (en) Topical formulations for the prevention of sexually transmitted disease and methods of producing the same
NZ600568A (en) Topical formulations for the prevention of sexually transmitted disease and methods of producing the same and which does not include an antimicrobial / antiviral agent
AU2012203566B1 (en) Topical formulations for the prevention of sexually transmitted disease and methods of producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL RO RU SD SK UA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2108143

Country of ref document: CA

122 Ep: pct application non-entry in european phase